These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 33904110)
1. The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients. Peng CW; Jeng WJ Hepatol Int; 2021 Apr; 15(2):527-528. PubMed ID: 33904110 [No Abstract] [Full Text] [Related]
2. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice. Ridruejo E; Marciano S; Galdame O; Reggiardo MV; Muñoz AE; Adrover R; Cocozzella D; Fernandez N; Estepo C; Mendizabal M; Romero GA; Levi D; Schroder T; Paz S; Fainboim H; Mandó OG; Gadano AC; Silva MO Ann Hepatol; 2014; 13(3):327-36. PubMed ID: 24756007 [TBL] [Abstract][Full Text] [Related]
3. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C? Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741 [TBL] [Abstract][Full Text] [Related]
4. Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma. Pellicelli AM; Vignally P; Messina V; Izzi A; Mazzoni E; Barlattani A; Bacca D; Romano M; Mecenate F; Stroffolini T; Furlan C; Picardi A; Gentilucci UV; Gulminetti R; Bonaventura ME; Villani R; D'Ambrosio C; Paffetti A; Mastropietro C; Marignani M; Fondacaro L; Cerasari G; Andreoli A; Barbarini G Ann Hepatol; 2014; 13(4):376-85. PubMed ID: 24927608 [TBL] [Abstract][Full Text] [Related]
5. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Liaw YF Hepatol Int; 2019 Nov; 13(6):665-673. PubMed ID: 31559604 [TBL] [Abstract][Full Text] [Related]
6. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. Tseng TC; Liu CJ; Su TH; Yang HC; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH J Infect Dis; 2012 Nov; 206(10):1521-31. PubMed ID: 22966125 [TBL] [Abstract][Full Text] [Related]
7. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon? Lampertico P; Viganò M; Colombo M Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860 [TBL] [Abstract][Full Text] [Related]
8. Early hepatitis B viral DNA clearance predicts treatment response at week 96. Fu XY; Tan DM; Liu CM; Gu B; Hu LH; Peng ZT; Chen B; Xie YL; Gong HY; Hu XX; Yao LH; Xu XP; Fu ZY; He LQ; Li SH; Long YZ; Li DH; Gu JL; Peng SF World J Gastroenterol; 2017 Apr; 23(16):2978-2986. PubMed ID: 28522916 [TBL] [Abstract][Full Text] [Related]
9. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350 [TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B. Oyagüez I; Buti M; Brosa M; Rueda M; Casado MA Ann Hepatol; 2017; 16(3):358-365. PubMed ID: 28425405 [TBL] [Abstract][Full Text] [Related]
12. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552 [TBL] [Abstract][Full Text] [Related]
13. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis]. Shi H; Li XY; Zhu JY; Lin CS; Zhang Y Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198 [No Abstract] [Full Text] [Related]
14. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication. Kamezaki H; Kanda T; Wu S; Nakamoto S; Arai M; Maruyama H; Fujiwara K; Imazeki F; Yokosuka O Scand J Gastroenterol; 2011 Sep; 46(9):1111-7. PubMed ID: 21623676 [TBL] [Abstract][Full Text] [Related]
15. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B. Huang YJ; Chang CS; Peng YC; Yeh HZ; Yang SS PLoS One; 2017; 12(3):e0174046. PubMed ID: 28350873 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients. Buti M; Morillas RM; Prieto M; Diago M; Pérez J; Solà R; Bonet L; Palau A; Testillano M; García-Samaniego J; Rodríguez M; Eur J Gastroenterol Hepatol; 2012 May; 24(5):535-42. PubMed ID: 22382708 [TBL] [Abstract][Full Text] [Related]
17. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649 [TBL] [Abstract][Full Text] [Related]
18. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549 [TBL] [Abstract][Full Text] [Related]
19. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis]. Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949 [TBL] [Abstract][Full Text] [Related]
20. [Comparison of the therapeutical effects of entecavir and lamvudine in treatment of HBeAg-positive chronic hepatitis B]. Hou HB; Deng LN; Li CP; Liu XR; Liu FQ Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):873-4. PubMed ID: 19958652 [No Abstract] [Full Text] [Related] [Next] [New Search]